BofA/Merrill Lynch Downgrades Pacira Pharmaceuticals (PCRX) to Underperform

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/19/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. TRMD
9. ACN
10. AZN

Go back to BofA/Merrill Lynch Downgrades Pacira Pharmaceuticals (PCRX) to Underperform

Pacira Pharmaceuticals (PCRX) PT Lifted to $136 at Piper Jaffray

February 25, 2015 9:49 AM EST

Piper Jaffray analyst David Amsellem reiterated an Overweight rating and bumped his price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $136.00 (from $134.00) following Q4 results yesterday.

Amsellem commented, "This morning, Pacira reported non-GAAP diluted EPS of $0.35, ahead of the Street estimate of $0.25, on Exparel sales of... More

Pacira Pharmaceuticals (PCRX) PT Lifted to $133 at Wedbush

February 25, 2015 6:57 AM EST

Wedbush analyst Liana Moussatos reiterated an Outperform rating and boosted her price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $133.00 (from $130.00) after preannounced Q4 EXPAREL sales and Q4 was 1st profitable quarter on GAAP basis.

Moussatos believe that the Street has overlooked the impact of EXPAREL's... More

Pacira Pharma (PCRX) Tops Q4 EPS by 8c

February 24, 2015 6:31 AM EST

Pacira Pharma (NASDAQ: PCRX) reported Q4 EPS of $0.35, $0.08 better than the analyst estimate of $0.27. Revenue for the quarter came in at $61.8 million versus the consensus estimate of $62.1 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.

... More